{
    "clinical_study": {
        "@rank": "99248", 
        "arm_group": {
            "arm_group_label": "high-risk", 
            "description": "high-risk is determined by the evaluation of the biomarkers of Q cell."
        }, 
        "biospec_descr": {
            "textblock": "tumor sample"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether Q cells separated from the glioma sample\n      are determinants in treatment response and prognosis of glioma patients"
        }, 
        "brief_title": "Treatment Response and Prognosis in Glioma Patients: Q Cell and Its Biological Characteristics", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Glioblastoma", 
            "Malignant Glioma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glioblastoma", 
                "Glioma"
            ]
        }, 
        "detailed_description": {
            "textblock": "The unique markers of Qcell were screened using the method of genomics and\n\n      proteomics, then these markers will be qualitatively and quantitatively evaluated in\n\n      glioblastoma patients by comparing their relationship with overrall\n\n      survival/progression-free survival and treatment response."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. >=18 years old\n\n          2. Primary Glioblastoma is newly diagnosed and confirmed histologically\n\n          3. Patient is expected to be treated with temozolomide and followed up routinely at the\n             study site.\n\n          4. Willing to sign the informed consent\n\n        Exclusion Criteria:\n\n          1. Currently enrolled in any other clinical study\n\n          2. History of any other malignancies\n\n          3. Refusal to give consent\n\n          4. No available tumor tissue for IDH analysis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with glioblastoma undergo operation and sufficient tumor specimens"
            }
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02047058", 
            "org_study_id": "NFGC-001-MCP"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "biomarker", 
            "Q cell", 
            "Overall survival", 
            "Progression-free survival"
        ], 
        "lastchanged_date": "January 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510515"
                }, 
                "name": "Nanfang Glioma Centre"
            }, 
            "status": "Active, not recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Multi-center, Prospective, Observational Study of Analysis of Q Cell Markers in Patients With Newly Diagnosed Primary Glioblastoma (Phase IV)", 
        "overall_contact": {
            "email": "yuleiguisi@gmail.com", 
            "last_name": "Songtao Qi, Doctor", 
            "phone": "+8620-61641804"
        }, 
        "overall_contact_backup": {
            "email": "battikindy@163.com", 
            "last_name": "Lei Yu, Doctor", 
            "phone": "+8620-61641806"
        }, 
        "overall_official": {
            "affiliation": "Nanfang Glioma centre, Guangzhou, China", 
            "last_name": "Songtao Qi, Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Participating centres collected data and submitted it by Email to the coordinating centre at the Nanfang Glioma Center. 300 patients with glioblastoma will be prospectively enrolled in this study. The unique markers of Q cell which had been screened using the method of genomics and proteomics will be measured and compared with progression-free and overall survival of patients. Regrettably,the markers of Q cell cannot yet be disclosed because of the confidentiality requirement. Progression-free survival (PFS) will be calculated from the day of \ufb01rst surgery until tumor progression, death, or end of follow-up. Overall survival (OS) will be calculated from the day of \ufb01rst surgery until death or end of follow-up. The effect of each single molecular marker on PFS and OS was investigated using the Cox proportional hazards model.", 
                "measure": "The effect of each single molecular marker of Q cell on progression-free survival", 
                "safety_issue": "Yes", 
                "time_frame": "3-5 days postoperatively"
            }, 
            {
                "description": "Participating centres collected data and submitted it by Email to the coordinating centre at the Nanfang Glioma Center. 300 patients with glioblastoma will be prospectively enrolled in this study. The unique markers of Q cell which had been screened using the method of genomics and proteomics will be measured and compared with progression-free and overall survival of patients. Regrettably,the markers of Q cell cannot yet be disclosed because of the confidentiality requirement. Progression-free survival (PFS) will be calculated from the day of \ufb01rst surgery until tumor progression, death, or end of follow-up. Overall survival (OS) will be calculated from the day of \ufb01rst surgery until death or end of follow-up. The effect of each single molecular marker on PFS and OS was investigated using the Cox proportional hazards model.", 
                "measure": "The effect of each single molecular marker of  Q cell on overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "3-5 days postoperatively"
            }
        ], 
        "reference": [
            {
                "PMID": "22034964", 
                "citation": "SongTao Q, Lei Y, Si G, YanQing D, HuiXia H, XueLin Z, LanXiao W, Fei Y. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci. 2012 Feb;103(2):269-73. doi: 10.1111/j.1349-7006.2011.02134.x. Epub 2011 Nov 28."
            }, 
            {
                "PMID": "21874255", 
                "citation": "Qi ST, Yu L, Lu YT, Ou YH, Li ZY, Wu LX, Yao F. IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas. Oncol Rep. 2011 Dec;26(6):1479-85. doi: 10.3892/or.2011.1428. Epub 2011 Aug 19."
            }, 
            {
                "PMID": "23079654", 
                "citation": "Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E, T\u00f6njes M, Sill M, Bender S, Kool M, Zapatka M, Becker N, Zucknick M, Hielscher T, Liu XY, Fontebasso AM, Ryzhova M, Albrecht S, Jacob K, Wolter M, Ebinger M, Schuhmann MU, van Meter T, Fr\u00fchwald MC, Hauch H, Pekrun A, Radlwimmer B, Niehues T, von Komorowski G, D\u00fcrken M, Kulozik AE, Madden J, Donson A, Foreman NK, Drissi R, Fouladi M, Scheurlen W, von Deimling A, Monoranu C, Roggendorf W, Herold-Mende C, Unterberg A, Kramm CM, Felsberg J, Hartmann C, Wiestler B, Wick W, Milde T, Witt O, Lindroth AM, Schwartzentruber J, Faury D, Fleming A, Zakrzewska M, Liberski PP, Zakrzewski K, Hauser P, Garami M, Klekner A, Bognar L, Morrissy S, Cavalli F, Taylor MD, van Sluis P, Koster J, Versteeg R, Volckmann R, Mikkelsen T, Aldape K, Reifenberger G, Collins VP, Majewski J, Korshunov A, Lichter P, Plass C, Jabado N, Pfister SM. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012 Oct 16;22(4):425-37. doi: 10.1016/j.ccr.2012.08.024."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02047058"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Other genetic alterations which have been previously reported include isocitrate dehydrogenase mutation, o6-methylguanine-DNA-methyltransferase methylation, 1p19q co-delation, Tumor Protein 53 (TP53) mutation, histone H3.3 (H3F3A) mutations, etc. The Chi-square test will be used to compare the genotype distribution.", 
            "measure": "We will correlate molecular markers of Q cell with other genetic alterations", 
            "safety_issue": "Yes", 
            "time_frame": "3-5 days postoperatively"
        }, 
        "source": "Nanfang Hospital of Southern Medical University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Guangzhou General Hospital of Guangzhou Military Command", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Daping Hospital and the Research Institute of Surgery of the Third Military Medical University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "First Affiliated Hospital of Fujian Medical University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The First Affiliated Hospital of Nanchang University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Capital Medical University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Tianjin Medical University General Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Shenzhen Second People's Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Huashan Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "West China Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Xiangya Hospital of Central South University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "First Hospital of Jilin University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "First Hospital of China Medical University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Qilu Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The Second Affiliated Hospital of Soochow University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Sun Yat-sen University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Guangzhou First Municipal People\u2019s Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Xi\u2019an Jiaotong University College of Medicine", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Southern Medical University, China", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Second Affiliated Hospital of Guangzhou Medical University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Nanfang Hospital of Southern Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "2 Years", 
        "verification_date": "January 2014"
    }
}